Close Menu

More articles about Diagnostics

Inspirata said that the partners will combine their digital pathology products to address challenges with traditional pathology testing for H. Pylori.

In one of two clearances, Beckman Coulter got the go-ahead to market its Access PCT chemiluminescent immunoassay for measuring levels of procalcitonin.

The Australian company also plans to offer 72 million new shares to eligible existing shareholders to raise additional funds.

Spartan's test is for the rapid, near-patient determination of a cardiac patient's genotype for aid in determining appropriate antiplatelet treatment.

Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.

A study of the firm's tests to detect bacterial vaginosis, yeast infections, and trichomoniasis, show they can potentially improve treatment for women with vaginitis.

While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.

Initiatives to develop commercial breath diagnostic systems reveal that developers are trying out lab-based mass spec systems and portable electronic noses.

The Cobas vivoDx MRSA test uses new bacteriophage technology based on bioluminescence to detect bacterial colonization in nasal swabs.

The firm has partnered with Leiden University Medical Center to study the use of its Immray platform to diagnose patients with rheumatoid arthritis.

Enzyre said its platform technology, which requires a small volume of blood, is able to measure up to 12 reactions simultaneously with high sensitivity and specificity.

The German company reported its quarterly earnings for the first time as a public company, following the completion of its IPO on Nov. 7.

The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.

In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.

The grants were awarded through the organization's Diagnostic Accelerator, a partnership between the charity and various philanthropic partners.

The guidelines place a stronger emphasis on pancreatic cancer risk genes, and broaden testing recommendations for those with Ashkenazi Jewish ancestry.

The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.

The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant to treat certain PIK3CA-mutated breast cancers.

The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.

The Dutch companies will use sequencing- and machine learning-based methods to quantify genomic instability-causing mutations in blood cells.

Pages